Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of distant metastasis and survival

Fady B. Geara, Giuseppe Sanguineti, Susan L. Tucker, Adam S. Garden, K. Kian Ang, William H. Morrison, Lester J. Peters

Research output: Contribution to journalArticle

Abstract

Purpose: This retrospective study was conducted to identify the prognostic factors for distant metastasis and survival in a population of 378 patients with nasopharyngeal carcinomas treated by radiation therapy alone. Materials and methods: All patients were treated at the University of Texas M.D. Anderson Cancer Center between 1954 and 1992, following a consistent dose and volume prescription policy. There were 286 males and 92 females. The median age was 52 years (range: 16-86 years). The majority of the patients were white Caucasians (282 patients, 75%). Tumors were classified as squamous cell carcinomas (193; 51%), lymphoepitheliomas (154; 41%), or unclassified carcinomas (31,8%). Three fourths of the patients presented with AJCC Stage IV disease (T4, N0-3, 118 patients; T1-3, N2-3 164 patients). The treatment techniques included opposed lateral fields with or without an anteroposterior or an anterior oblique pairs for dose supplementation to the primary site. Average total doses per T-stage ranged between 60.2 and 72.0 Gy. Median follow-up time was 10 years (range 0.3 to 28.6 years). Results: A total of 103 patients (27%) developed distant metastases at a median time of 8 months (range: 1-90 months). Actuarial rates for distant metastasis were 30%, 32%, 32% at 5, 10, and 20 years, respectively. Actuarial rates for disease specific survival at the same time points were 53%, 45%, and 39% with 184 patients (49%) dying of their nasopharyngeal cancer. Advanced T-stage, N-stage, and non-lymphoepithelioma histology were independent adverse prognostic factors for disease specific survival. Advanced N-stage and low neck disease were independent adverse prognostic factors for distant metastasis with a very high rate of distant metastases for those patients who presented with both adverse factors (relative risk 7.86). On average, patients with distant metastasis lived 5 months after they were diagnosed with metastatic disease (range: 0-172 months), although four patients (4%) survived more than 5 years after diagnosis. Conclusions: This study demonstrates good long term survival rates after definitive radiotherapy for patients with nasopharyngeal carcinomas. Patients with advanced and lower neck disease have the highest risk of developing distant failures. Such patients can be considered the reference risk group to test the value of adjunctive chemotherapy.

Original languageEnglish
Pages (from-to)53-61
Number of pages9
JournalRadiotherapy and Oncology
Volume43
Issue number1
DOIs
Publication statusPublished - Apr 1997

Fingerprint

Nasopharynx
Radiotherapy
Neoplasm Metastasis
Carcinoma
Survival
Neck
Nasopharyngeal Neoplasms
Prescriptions

Keywords

  • distant metastasis
  • nasopharyngeal cancer
  • radiotherapy
  • survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

Carcinoma of the nasopharynx treated by radiotherapy alone : Determinants of distant metastasis and survival. / Geara, Fady B.; Sanguineti, Giuseppe; Tucker, Susan L.; Garden, Adam S.; Ang, K. Kian; Morrison, William H.; Peters, Lester J.

In: Radiotherapy and Oncology, Vol. 43, No. 1, 04.1997, p. 53-61.

Research output: Contribution to journalArticle

Geara, Fady B. ; Sanguineti, Giuseppe ; Tucker, Susan L. ; Garden, Adam S. ; Ang, K. Kian ; Morrison, William H. ; Peters, Lester J. / Carcinoma of the nasopharynx treated by radiotherapy alone : Determinants of distant metastasis and survival. In: Radiotherapy and Oncology. 1997 ; Vol. 43, No. 1. pp. 53-61.
@article{5328c5ad187c4b8a9e6abf340524cbcf,
title = "Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of distant metastasis and survival",
abstract = "Purpose: This retrospective study was conducted to identify the prognostic factors for distant metastasis and survival in a population of 378 patients with nasopharyngeal carcinomas treated by radiation therapy alone. Materials and methods: All patients were treated at the University of Texas M.D. Anderson Cancer Center between 1954 and 1992, following a consistent dose and volume prescription policy. There were 286 males and 92 females. The median age was 52 years (range: 16-86 years). The majority of the patients were white Caucasians (282 patients, 75{\%}). Tumors were classified as squamous cell carcinomas (193; 51{\%}), lymphoepitheliomas (154; 41{\%}), or unclassified carcinomas (31,8{\%}). Three fourths of the patients presented with AJCC Stage IV disease (T4, N0-3, 118 patients; T1-3, N2-3 164 patients). The treatment techniques included opposed lateral fields with or without an anteroposterior or an anterior oblique pairs for dose supplementation to the primary site. Average total doses per T-stage ranged between 60.2 and 72.0 Gy. Median follow-up time was 10 years (range 0.3 to 28.6 years). Results: A total of 103 patients (27{\%}) developed distant metastases at a median time of 8 months (range: 1-90 months). Actuarial rates for distant metastasis were 30{\%}, 32{\%}, 32{\%} at 5, 10, and 20 years, respectively. Actuarial rates for disease specific survival at the same time points were 53{\%}, 45{\%}, and 39{\%} with 184 patients (49{\%}) dying of their nasopharyngeal cancer. Advanced T-stage, N-stage, and non-lymphoepithelioma histology were independent adverse prognostic factors for disease specific survival. Advanced N-stage and low neck disease were independent adverse prognostic factors for distant metastasis with a very high rate of distant metastases for those patients who presented with both adverse factors (relative risk 7.86). On average, patients with distant metastasis lived 5 months after they were diagnosed with metastatic disease (range: 0-172 months), although four patients (4{\%}) survived more than 5 years after diagnosis. Conclusions: This study demonstrates good long term survival rates after definitive radiotherapy for patients with nasopharyngeal carcinomas. Patients with advanced and lower neck disease have the highest risk of developing distant failures. Such patients can be considered the reference risk group to test the value of adjunctive chemotherapy.",
keywords = "distant metastasis, nasopharyngeal cancer, radiotherapy, survival",
author = "Geara, {Fady B.} and Giuseppe Sanguineti and Tucker, {Susan L.} and Garden, {Adam S.} and Ang, {K. Kian} and Morrison, {William H.} and Peters, {Lester J.}",
year = "1997",
month = "4",
doi = "10.1016/S0167-8140(97)01914-2",
language = "English",
volume = "43",
pages = "53--61",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Carcinoma of the nasopharynx treated by radiotherapy alone

T2 - Determinants of distant metastasis and survival

AU - Geara, Fady B.

AU - Sanguineti, Giuseppe

AU - Tucker, Susan L.

AU - Garden, Adam S.

AU - Ang, K. Kian

AU - Morrison, William H.

AU - Peters, Lester J.

PY - 1997/4

Y1 - 1997/4

N2 - Purpose: This retrospective study was conducted to identify the prognostic factors for distant metastasis and survival in a population of 378 patients with nasopharyngeal carcinomas treated by radiation therapy alone. Materials and methods: All patients were treated at the University of Texas M.D. Anderson Cancer Center between 1954 and 1992, following a consistent dose and volume prescription policy. There were 286 males and 92 females. The median age was 52 years (range: 16-86 years). The majority of the patients were white Caucasians (282 patients, 75%). Tumors were classified as squamous cell carcinomas (193; 51%), lymphoepitheliomas (154; 41%), or unclassified carcinomas (31,8%). Three fourths of the patients presented with AJCC Stage IV disease (T4, N0-3, 118 patients; T1-3, N2-3 164 patients). The treatment techniques included opposed lateral fields with or without an anteroposterior or an anterior oblique pairs for dose supplementation to the primary site. Average total doses per T-stage ranged between 60.2 and 72.0 Gy. Median follow-up time was 10 years (range 0.3 to 28.6 years). Results: A total of 103 patients (27%) developed distant metastases at a median time of 8 months (range: 1-90 months). Actuarial rates for distant metastasis were 30%, 32%, 32% at 5, 10, and 20 years, respectively. Actuarial rates for disease specific survival at the same time points were 53%, 45%, and 39% with 184 patients (49%) dying of their nasopharyngeal cancer. Advanced T-stage, N-stage, and non-lymphoepithelioma histology were independent adverse prognostic factors for disease specific survival. Advanced N-stage and low neck disease were independent adverse prognostic factors for distant metastasis with a very high rate of distant metastases for those patients who presented with both adverse factors (relative risk 7.86). On average, patients with distant metastasis lived 5 months after they were diagnosed with metastatic disease (range: 0-172 months), although four patients (4%) survived more than 5 years after diagnosis. Conclusions: This study demonstrates good long term survival rates after definitive radiotherapy for patients with nasopharyngeal carcinomas. Patients with advanced and lower neck disease have the highest risk of developing distant failures. Such patients can be considered the reference risk group to test the value of adjunctive chemotherapy.

AB - Purpose: This retrospective study was conducted to identify the prognostic factors for distant metastasis and survival in a population of 378 patients with nasopharyngeal carcinomas treated by radiation therapy alone. Materials and methods: All patients were treated at the University of Texas M.D. Anderson Cancer Center between 1954 and 1992, following a consistent dose and volume prescription policy. There were 286 males and 92 females. The median age was 52 years (range: 16-86 years). The majority of the patients were white Caucasians (282 patients, 75%). Tumors were classified as squamous cell carcinomas (193; 51%), lymphoepitheliomas (154; 41%), or unclassified carcinomas (31,8%). Three fourths of the patients presented with AJCC Stage IV disease (T4, N0-3, 118 patients; T1-3, N2-3 164 patients). The treatment techniques included opposed lateral fields with or without an anteroposterior or an anterior oblique pairs for dose supplementation to the primary site. Average total doses per T-stage ranged between 60.2 and 72.0 Gy. Median follow-up time was 10 years (range 0.3 to 28.6 years). Results: A total of 103 patients (27%) developed distant metastases at a median time of 8 months (range: 1-90 months). Actuarial rates for distant metastasis were 30%, 32%, 32% at 5, 10, and 20 years, respectively. Actuarial rates for disease specific survival at the same time points were 53%, 45%, and 39% with 184 patients (49%) dying of their nasopharyngeal cancer. Advanced T-stage, N-stage, and non-lymphoepithelioma histology were independent adverse prognostic factors for disease specific survival. Advanced N-stage and low neck disease were independent adverse prognostic factors for distant metastasis with a very high rate of distant metastases for those patients who presented with both adverse factors (relative risk 7.86). On average, patients with distant metastasis lived 5 months after they were diagnosed with metastatic disease (range: 0-172 months), although four patients (4%) survived more than 5 years after diagnosis. Conclusions: This study demonstrates good long term survival rates after definitive radiotherapy for patients with nasopharyngeal carcinomas. Patients with advanced and lower neck disease have the highest risk of developing distant failures. Such patients can be considered the reference risk group to test the value of adjunctive chemotherapy.

KW - distant metastasis

KW - nasopharyngeal cancer

KW - radiotherapy

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=0030891823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030891823&partnerID=8YFLogxK

U2 - 10.1016/S0167-8140(97)01914-2

DO - 10.1016/S0167-8140(97)01914-2

M3 - Article

C2 - 9165137

AN - SCOPUS:0030891823

VL - 43

SP - 53

EP - 61

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 1

ER -